Dr. Natalie Christian is an Executive Director in the Global Vaccine and Biologics Commercialization organization of Merck's Manufacturing Division. She leads the project leadership group responsible for leading Development and Commercialization Teams (DCT) for late-stage large molecule and vaccine pipeline programs. Previously, she led DCTs for live virus vaccine programs inclusive of COVID-19, Cytomegalovirus, and Dengue as well as held positions within the Technical Services organization supporting GARDASIL®9, GARDASIL®, RECOMBIVAX®HB, VARIVAX®, RotaTeq®, and PNEUMOVAX®23. Dr. Christian earned her Ph.D. at the University of Pennsylvania Bioengineering school where she developed polymeric-based near-infrared nanoparticles for in vivo imaging of dendritic cell migration. She received her B.S. in Chemical Engineering from the University of Kentucky.